<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354754</url>
  </required_header>
  <id_info>
    <org_study_id>CLYS228X2202</org_study_id>
    <nct_id>NCT03354754</nct_id>
  </id_info>
  <brief_title>LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)</brief_title>
  <official_title>A Randomized, Controlled, Evaluator-blinded, Multi-center Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety, and Tolerability in Patients With Complicated Intra-abdominal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate whether LYS228 can be developed for the treatment of
      complicated intra-abdominal infections.

      It was planned that LYS228 exposure across patients with varying renal function would be
      evaluated during the study to confirm that LYS228 concentrations are predicted to be adequate
      to treat the patient population. It was planned that the PK exposure of the initial 8
      patients would be analyzed.

      PK analysis was not conducted as per protocol the first analysis required 8 patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was closed as part of the out-licensure of the drug to Boston Pharmaceuticals, which
    will continue further clinical development of LYS228/BOS-228
  </why_stopped>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Actual">September 24, 2018</completion_date>
  <primary_completion_date type="Actual">September 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>A blinded evaluator performed the safety and efficacy assessments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Clinical success is defined as resolution, or substantial improvement (i.e. reduction of severity of all baseline signs and symptoms and worsening of none) of all or most baseline signs and symptoms of cIAI infection without the need for additional antibiotic therapy other than any oral antibiotics given to complete treatment at home following discontinuation of Study Drug and no drainage or surgical reintervention required 96 hours after the start of Study Drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The Time to Reach the Maximum Concentration After Drug Administration (Tmax)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The Systemic (or Total Body) Clearance From Plasma Following Intravenous Administration (CL)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The Volume of Distribution at Steady State Following Intravenous Administration (Vss)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Pharmacokinetics (PK) of LYS228: The Terminal Elimination Half-life (T1/2)</measure>
    <time_frame>Day 5</time_frame>
    <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>Daily</time_frame>
    <description>Number of patients with at least one Adverse Event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Response at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>Microbiologic success at 28 days after randomization determined by microbial growth in culture from the intra-abdominal focus of infection when available or presumed eradication based on clinical success</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Intra-abdominal Infections</condition>
  <arm_group>
    <arm_group_label>LYS228</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion every 6 hours for at least 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV infusion of standard of care antibiotics for at least 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LYS228</intervention_name>
    <description>LYS228 IV infusion every 6 hours</description>
    <arm_group_label>LYS228</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care therapy</intervention_name>
    <description>IV infusion of standard of care antibiotics</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients 18 to 85 years of age with visual confirmation (presence of
             pus within the abdominal cavity) of an intra-abdominal infection associated with
             peritonitis including at least one inclusionary diagnosis during surgical
             intervention.

        Exclusion Criteria

          -  Any of the excluded diagnoses: abdominal wall abscess, small bowel obstruction,
             traumatic bowel perforation undergoing surgery within 12 hours, perforation of
             gastroduodenal ulcer with surgery within 24 hours, an intra-abdominal process that is
             not likely caused by infection.

          -  Pre-operative treatment of any duration with non-study Drug systemic antibiotic
             therapy for peritonitis or abscess is not allowed unless certain criteria are met.

          -  Concomitant bacterial infection at time of enrollment requiring non-Study Drug
             antibiotics and that may interfere with the evaluation of clinical response to the
             study antibiotic.

          -  Known non-abdominal source of infection, including endocarditis, osteomyelitis,
             abscess, meningitis, or pneumonia diagnosed within 7 days prior to enrollment.

          -  Patient has an Acute Physiology and Chronic Health Evaluation II (APACHE II) score &gt;
             30 or is considered, in the judgement of the investigator, unlikely to survive 4 weeks
             (e.g. rapidly progressive terminal illness, including septic shock).

          -  Patients that meet sepsis criteria as defined by the quick sequential sepsis-related
             organ failure assessment (qSOFA).

          -  Women of child-bearing potential unless they are using highly effective methods of
             contraception during dosing and for 7 days after stopping study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <results_first_submitted>September 18, 2019</results_first_submitted>
  <results_first_submitted_qc>September 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2019</results_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intra-abdominal infection</keyword>
  <keyword>LYS228</keyword>
  <keyword>beta-lactam antibiotics</keyword>
  <keyword>creatinine clearance</keyword>
  <keyword>enterobacteriaceae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03354754/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03354754/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Approximately 60 patients were planned to be randomized to LYS228 or a comparator (standard of care therapy preferably piperacillin/tazobactam) in a 2:1 ratio.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>LYS228</title>
          <description>IV infusion every 6 hours for at least 5 days</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>IV infusion of standard of care antibiotics for at least 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LYS228</title>
          <description>IV infusion every 6 hours for at least 5 days</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>IV infusion of standard of care antibiotics for at least 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" lower_limit="63" upper_limit="64"/>
                    <measurement group_id="B2" value="63" lower_limit="63" upper_limit="63"/>
                    <measurement group_id="B3" value="63" lower_limit="63" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Success at Day 28</title>
        <description>Clinical success is defined as resolution, or substantial improvement (i.e. reduction of severity of all baseline signs and symptoms and worsening of none) of all or most baseline signs and symptoms of cIAI infection without the need for additional antibiotic therapy other than any oral antibiotics given to complete treatment at home following discontinuation of Study Drug and no drainage or surgical reintervention required 96 hours after the start of Study Drug.</description>
        <time_frame>Day 28</time_frame>
        <population>All patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success at Day 28</title>
          <description>Clinical success is defined as resolution, or substantial improvement (i.e. reduction of severity of all baseline signs and symptoms and worsening of none) of all or most baseline signs and symptoms of cIAI infection without the need for additional antibiotic therapy other than any oral antibiotics given to complete treatment at home following discontinuation of Study Drug and no drainage or surgical reintervention required 96 hours after the start of Study Drug.</description>
          <population>All patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)</title>
        <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
        <time_frame>Day 5</time_frame>
        <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of LYS228: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)</title>
          <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
          <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics (PK) of LYS228: The Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</title>
        <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
        <time_frame>Day 5</time_frame>
        <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of LYS228: The Observed Maximum Plasma Concentration Following Drug Administration (Cmax)</title>
          <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
          <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics (PK) of LYS228: The Time to Reach the Maximum Concentration After Drug Administration (Tmax)</title>
        <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
        <time_frame>Day 5</time_frame>
        <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of LYS228: The Time to Reach the Maximum Concentration After Drug Administration (Tmax)</title>
          <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
          <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics (PK) of LYS228: The Systemic (or Total Body) Clearance From Plasma Following Intravenous Administration (CL)</title>
        <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
        <time_frame>Day 5</time_frame>
        <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of LYS228: The Systemic (or Total Body) Clearance From Plasma Following Intravenous Administration (CL)</title>
          <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
          <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics (PK) of LYS228: The Volume of Distribution at Steady State Following Intravenous Administration (Vss)</title>
        <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
        <time_frame>Day 5</time_frame>
        <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of LYS228: The Volume of Distribution at Steady State Following Intravenous Administration (Vss)</title>
          <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
          <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Pharmacokinetics (PK) of LYS228: The Terminal Elimination Half-life (T1/2)</title>
        <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
        <time_frame>Day 5</time_frame>
        <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetics (PK) of LYS228: The Terminal Elimination Half-life (T1/2)</title>
          <description>Calculated based on LYS228 concentration in blood at different time points following drug administration on Day 5</description>
          <population>PK analysis for the 2 patients enrolled that received LYS228 was not conducted as per protocol the first analysis required 8 patients</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Number of patients with at least one Adverse Event</description>
        <time_frame>Daily</time_frame>
        <population>All patients</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Number of patients with at least one Adverse Event</description>
          <population>All patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Response at Day 28</title>
        <description>Microbiologic success at 28 days after randomization determined by microbial growth in culture from the intra-abdominal focus of infection when available or presumed eradication based on clinical success</description>
        <time_frame>Day 28</time_frame>
        <population>All patients with a microbiological response assessment</population>
        <group_list>
          <group group_id="O1">
            <title>LYS228</title>
            <description>IV infusion every 6 hours for at least 5 days</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>IV infusion of standard of care antibiotics for at least 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Response at Day 28</title>
          <description>Microbiologic success at 28 days after randomization determined by microbial growth in culture from the intra-abdominal focus of infection when available or presumed eradication based on clinical success</description>
          <population>All patients with a microbiological response assessment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until day 28.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LYS228</title>
          <description>IV infusion every 6 hours for at least 5 days</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>IV infusion of standard of care antibiotics for at least 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

